Ending Discrimination in COVID-19 Treatments Act
This bill prohibits consideration of certain factors, including vaccination status, in decisions about an individual's access to federally provided monoclonal antibody therapies to treat COVID-19.
As a condition of receiving the therapies from the federal government, states must ensure that providers do not consider specified demographic characteristics, veteran status, or political ideology or speech when determining a patient's eligibility for such therapies.
To prohibit the consideration of patients' race, color, religion, sex, 
 national origin, age, disability, vaccination status, veteran status, 
    or political ideology or speech in determining eligibility for 
    monoclonal antibody doses distributed by the Federal Government.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Ending Discrimination in COVID-19 
Treatments Act''.

SEC. 2. ELIGIBILITY TO RECEIVE MONOCLONAL ANTIBODY TREATMENT.

    The Secretary of Health and Human Services shall require States, as 
a condition for receipt of monoclonal antibody doses from the Federal 
Government, to ensure that providers receiving distributions of such 
monoclonal antibody doses from such States do not take into 
consideration the race, color, religion, sex, national origin, age, 
disability, vaccination status, veteran status, or political ideology 
or speech of a patient in determining whether a patient is eligible to 
receive such treatment.
                                 <all>
Ending Discrimination in COVID–19 Treatments Act
A bill to prohibit the consideration of patients' race, color, religion, sex, national origin, age, disability, vaccination status, veteran status, or political ideology or speech in determining eligibility for monoclonal antibody doses distributed by the Federal Government.
Ending Discrimination in COVID–19 Treatments Act
Sen. Cruz, Ted